Maia Biotechnology (MAIA) plans to start enrollment of certain patients resistant to checkpoint inhibitors and chemotherapy in a phase 3 study of THIO-104 for non-small lung cancer in H2.
The trial will evaluate the efficacy of THIO-104 administered in sequence with a checkpoint inhibitor to improve the overall survival of patients whose cancer has continued to grow after two previous lines of systemic treatment, the company said Thursday in a statement.
The study will enroll up to 300 patients in Asia, Europe and the US to compare the treatment with chemotherapy in 1-to-1 randomization, the company said.
Price: 1.85, Change: +0.01, Percent Change: +0.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.